"Flucytosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fluorinated cytosine analog that is used as an antifungal agent.
- CSP Brand of Flucytosine
- Roche Brand of Flucytosine
- Allphar Brand of Flucytosine
- Dermatech Brand of Flucytosine
- ICN Pharmaceuticals Brand of Flucytosine
Below are MeSH descriptors whose meaning is more general than "Flucytosine".
Below are MeSH descriptors whose meaning is more specific than "Flucytosine".
This graph shows the total number of publications written about "Flucytosine" by people in Harvard Catalyst Profiles by year, and whether "Flucytosine" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Flucytosine" by people in Profiles.
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? Clin Infect Dis. 2023 03 04; 76(5):944-949.
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med. 2022 03 24; 386(12):1109-1120.
Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno-venous hemofiltration and intermittent hemodialysis: A case report. Transpl Infect Dis. 2021 Aug; 23(4):e13575.
Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. Am J Trop Med Hyg. 2020 08; 103(2):713-718.
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy. J Natl Cancer Inst. 2019 03 01; 111(3):283-291.
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials. 2018 Nov 23; 19(1):649.
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018 09 03; 20(10):1383-1392.
Psychosis Due to Disseminated Cryptococcal Infection and Delirium in an Immunocompetent Patient: A Case Report and Review of the Literature. Psychosomatics. 2018 Jul - Aug; 59(4):394-399.
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. Neurosurgery. 2016 Sep; 79(3):481-91.
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 06 01; 8(341):341ra75.